Straits Times Index
3,380.84 -5.09 (-0.15%) S&P 500
4,134.90 +23.82 (+0.58%) Dow
33,956.33 +65.31 (+0.19%) Nasdaq
11,993.44 +105.99 (+0.89%) BTC-USD
23,085.32 -8.17 (-0.04%) CMC Crypto 200
531.55 +5.59 (+1.06%)
ABT Jan 2024 155.000 call
| Previous close | 1.1500 |
| Open | 1.1500 |
| Bid | 0.4900 |
| Ask | 0.6000 |
| Strike | 155.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.1500 - 1.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
- Motley Fool
Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?
Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Is Abbott a bad-news buy that could turn things around in 2023, or has this once-safe healthcare stock become too risky of an investment to be holding right now? Last month, Abbott reported its fourth-quarter and year-end results for 2022.
- Motley Fool
Is This Dividend King a Buy for Income Investors?
No matter which way the market goes, the payouts of companies with decades of dividend growth behind them tend to go in one direction: up. Abbott Laboratories' (NYSE: ABT) 50-year dividend growth streak makes it one of just 43 Dividend Kings. With 113,000 employees and a presence in more than 160 countries, Abbott is among the largest healthcare companies in the world.
- Zacks
Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release
Ensign Group's (ENSG) fourth-quarter results indicate higher skilled services revenue and improved occupancies, partly offset by the increased cost of services.
